The trouble for the brokers nd the market wanting in is if good HCV results come in it won't just stop at HCV competitors for valuation. It will also act to validate the entire platform, and bring in the cash to expand that platform and patents, further adding to the valuation difficulties.
It'll be a hell of a lot of fun (for us LT holders) to watch them trying to value the stock if HCV results come back solid.
BLT Price at posting:
55.5¢ Sentiment: Buy Disclosure: Held
